Taysha Gene Therapies (TSHA) Tops Q3 EPS by 19c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($0.64), $0.19 better than the analyst estimate of ($0.83).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown